Medical schools across the country are offering courses that take students out of large lectures and turn them from doodlers into detectives--following a model designed by Harvard Medical School (HMS) over a decade ago.
HMS's New Pathway program is perhaps the most comprehensive example of "problem-based learning"--a philosophy of teaching that has students work in small groups to solve specific clinical "cases."
HMS assembled this program in the mid-Eighties and has used it for about 60 percent of its instruction since.
Now, more and more medical schools are using similar programs--encouraged by what HMS officials say is a high rate of satisfaction among students.
According to HMS Dean for Medical Education Daniel D. Federman '49, HMS developed the new curriculum in the early Eighties by combining elements of problem-based learning programs at other schools.
"We did not invent a single element, but we did put together the whole package," Federman says.
The result was named the New Pathway, tested in 1985 and 1986 and was set in place permanently in 1987.
Learning by Doing
Read more in News
War Means War in KosovoRecommended Articles
-
Dean Brings Human Touch to ScienceFor Dr. Daniel Federman '49, it's all about interpersonal relations. A charismatic smile and firm handshake greet all who enter
-
Exxon Grants Med School $500,000The Harvard Medical School(HMS) announced this week that the Exxon Foundation has granted $500,000 over the next three years to
-
Med School Class of '99: A Closer LookFifty years ago, Harvard Medical School (HMS) admitted its first two women candidates for the degree of doctor of medicine.
-
Future Physicians Learn How to LearnEditor's Note: This is the first in a two-part series examining the New Pathway curriculum at Harvard Medical School. In
-
In the Limelight: Students in `New Pathway'Editor's Note: This is the second of a two-part series on the New Pathway curriculum at Harvard Medical School. Luanda
-
HMS Report: Study Subjects Need ProtectionResearchers need to better protect patients in clinical trials and tighten oversight of medical studies, a national advisory panel headed